US · MCRB · BIOTECHNOLOGY
Seres Therapeutics, Inc. (MCRB) intrinsic value and stock valuation
$1.24as of 2026-11-21 · Mkt cap 48.47M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Seres Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values MCRB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MCRB’s statements →
Seres Therapeutics, Inc. Graham Number
Graham Number: $8.50d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $790K | $0.00 | $0.00 | $0.00 | $144.9M |
| Operating income | -$-93.97M | -$-121.31M | -$-195.1M | -$-179.91M | -$-64.49M |
| Net income | $5.7M | -$-146.57M | -$-113.72M | -$-250.16M | -$-65.58M |
| EPSd | $642.6K | -$-18.86M | -$-17.77M | -$-46.33M | -$-14.29M |
| Operating cash flow | $1.12M | -$-148.61M | -$-117.35M | -$-228.82M | $6.69M |
| Capital expenditure | -$-250K | -$-380K | -$-7.97M | -$-9.82M | -$-9.57M |
| Free cash flow | $860K | -$-148.99M | -$-125.33M | -$-238.64M | -$-2.88M |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Total debt | $83M | $91.6M | $198.8M | $162.6M | $49.2M |
| Net debt | $37.2M | $60.9M | $70.8M | -$-440K | -$-130.79M |
| Total equity | $44.2M | $13.8M | -$-44.86M | $10.8M | $131.5M |
| Cash and short-term investments | $45.8M | $30.8M | $128M | $181.3M | $290.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $790K | $0.00 | $0.00 | $0.00 | $144.9M |
| Cost of revenue | $4.13M | $3.53M | $19.3M | $0.00 | $0.00 |
| Gross profit | -$-3.34M | -$-3.53M | -$-19.34M | $0.00 | $144.9M |
| Research and development expenses | $49.1M | $64.6M | $117.6M | $109.7M | $141.9M |
| Selling, general and administrative expenses | $39.2M | $53.2M | $77.5M | $70.3M | $69.3M |
| Other expenses | $2.41M | $0.00 | -$-19.34M | $0.00 | -$-1.73M |
| Operating expenses | $90.6M | $117.8M | $175.8M | $179.9M | $209.4M |
| Cost and expenses | $94.8M | $121.3M | $195.1M | $179.9M | $209.4M |
| Interest income | $2.23M | $3.97M | $7.3M | $3.06M | $2.87M |
| Interest expense | $0.00 | $0.00 | $13.2M | $6.02M | $2.91M |
| Depreciation and amortization | $4.13M | $5.47M | $6.24M | $6.63M | $5.95M |
| Ebitda | $9.83M | -$-120.3M | -$-181.42M | -$-170.93M | -$-56.72M |
| Operating income | -$-93.97M | -$-121.31M | -$-195.1M | -$-179.91M | -$-64.49M |
| Total other income/expenses, net | $99.7M | -$-4.46M | $4.97M | -$-3.67M | -$-1.08M |
| Income before tax | $5.7M | -$-125.77M | -$-190.13M | -$-183.58M | -$-65.58M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $5.7M | -$-146.57M | -$-113.72M | -$-250.16M | -$-65.58M |
| Weighted average shares outstanding | $8.86M | $7.77M | $6.4M | $5.4M | $4.59M |
| Weighted average diluted shares outstanding | $8.87M | $7.77M | $6.4M | $5.4M | $4.59M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $45.8M | $30.8M | $128M | $181.3M | $290.7M |
| Net receivables | $360K | $4.75M | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $29.7M | $0.00 | $0.00 |
| Total current assets | $49.4M | $38.7M | $175.4M | $194.8M | $303.6M |
| Property, plant and equipment, net | $80.1M | $92.4M | $108M | $134M | $36.2M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $8.67M | $8.67M | $9.59M | $9.59M | $490K |
| Total non-current assets | $88.8M | $101.1M | $183.2M | $154M | $51.2M |
| Total assets | $138.2M | $139.8M | $358.6M | $348.8M | $354.9M |
| Accounts payable | $1.68M | $4.08M | $3.64M | $17.4M | $13.7M |
| Short-term debt | $10.4M | $8.67M | $5.59M | $4.06M | $6.61M |
| Deferred revenue | $0.00 | $0.00 | $7.73M | $4.26M | $16.8M |
| Total current liabilities | $19.3M | $41.2M | $98.7M | $85.6M | $82.3M |
| Long-term debt | $72.6M | $83M | $193.2M | $158.5M | $42.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $95.4M | $92.4M | $87M |
| Total non-current liabilities | $74.7M | $84.8M | $304.8M | $252.4M | $141.1M |
| Capital lease obligations | $72.6M | $91.6M | $97.2M | $111.5M | $24.6M |
| Total liabilities | $94M | $126M | $403.5M | $338M | $223.4M |
| Common stock | $10K | $170K | $140K | $120K | $90K |
| Retained earnings | -$-972.4M | -$-978.1M | -$-978.24M | -$-864.51M | -$-614.35M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | -$-10K | -$-60K |
| Total equity | $44.2M | $13.8M | -$-44.86M | $10.8M | $131.5M |
| Total investments | $8.67M | $8.67M | $9.59M | $27.9M | $111.2M |
| Total debt | $83M | $91.6M | $198.8M | $162.6M | $49.2M |
| Net debt | $37.2M | $60.9M | $70.8M | -$-440K | -$-130.79M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $5.7M | $140K | -$-113.72M | -$-250.16M | -$-65.58M |
| Depreciation and amortization | $4.13M | $5.47M | $6.24M | $6.63M | $5.95M |
| Stock-based compensation | $10.8M | $21M | $34.1M | $25.5M | $20.2M |
| Change in working capital | -$-27.78M | -$-65.51M | -$-58.98M | -$-18.39M | $41.5M |
| Accounts receivable | $1.55M | -$-2.07M | -$-8.67M | $0.00 | $9.39M |
| Inventory | $0.00 | -$-33.8M | -$-29.65M | $0.00 | $0.00 |
| Accounts payable | -$-2.4M | -$-2.94M | -$-11.58M | $2.2M | $9.36M |
| Net cash provided by operating activities | $1.12M | -$-148.61M | -$-117.35M | -$-228.82M | $6.69M |
| Investments in property, plant and equipment | -$-250K | -$-380K | -$-7.97M | -$-9.82M | -$-9.57M |
| Acquisitions, net | $210K | $0.00 | $0.00 | -$-92.25M | $0.00 |
| Net cash used for investing activities | -$-40K | $142.3M | $10.6M | $82.4M | $64.1M |
| Common stock issued | $13.9M | $23.5M | $18.2M | $101.2M | $2.13M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $13.9M | -$-90.37M | $71.7M | $129.6M | $1.18M |
| Net change in cash | $15M | -$-96.69M | -$-35.06M | -$-16.79M | $72M |
| Cash at end of period | $54.4M | $39.5M | $136.2M | $171.2M | $188M |
| Operating cash flow | $1.12M | -$-148.61M | -$-117.35M | -$-228.82M | $6.69M |
| Capital expenditure | -$-250K | -$-380K | -$-7.97M | -$-9.82M | -$-9.57M |
| Free cash flow | $860K | -$-148.99M | -$-125.33M | -$-238.64M | -$-2.88M |
Line items
Line items
Line items
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.
- CEO
- Richard N. Kender
- Employees
- 66
- Beta
- 0.21
Explore
Frequently asked questions
What is the intrinsic value of Seres Therapeutics, Inc. (MCRB)?
InvestorsCraft does not currently publish an intrinsic value for MCRB. How the IC value is calculated.
Is MCRB undervalued?
InvestorsCraft does not publish an undervaluation signal for MCRB at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.